4D Molecular Therapeutics, Inc. (FDMT)
$12.06
Rating:
Recommendation:
-
| Symbol | FDMT |
|---|---|
| Price | $12.06 |
| Beta | 2.357 |
| Volume Avg. | 0.30M |
| Market Cap | 546.667M |
| Shares () | - |
| 52 Week Range | 6.58-26.49 |
| 1y Target Est | - |
| DCF Unlevered | FDMT DCF -> | |
|---|---|---|
| DCF Levered | FDMT LDCF -> | |
| ROE | 185.68% | Strong Buy |
| ROA | -30.71% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -4.19% | Neutral |
| P/E | -4.07 | Strong Sell |
| P/B | -1.24 | Sell |
Latest FDMT news
About
Download (Excel)4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.